This database contains 70 studies, archived under the term: "brain"
Click here to filter this large number of results.
Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease
Solé-Padullés, Cristina,
Bartrés-Faz, David,
Lladó, Albert,
Bosch, Beatriz,
Peña-Gómez, Cleofé,
Castellví, Magdalena,
Rami, Lorena,
Bargalló, Nuria,
Sánchez-Valle, Raquel,
Molinuevo, José Luis
Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer’s disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comparable AD patients relative to the treated groups. Fifteen patients recently diagnosed of […]
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene
Snowden, Julie S.,
Hu, Quan,
Rollinson, Sara,
Halliwell, Nicola,
Robinson, Andrew,
Davidson, Yvonne S.,
Momeni, Parastoo,
Baborie, Atik,
Griffiths, Timothy D.,
Jaros, Evelyn,
Perry, Robert H.,
Richardson, Anna,
Pickering-Brown, Stuart M.,
Neary, David,
Mann, David M. A.
Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. Recent descriptions of a pathological sub-type that is ubiquitin positive, TDP-43 negative and immunostains positive for the Fused in Sarcoma protein (FUS) raises the question whether it is associated with a distinct clinical phenotype identifiable on clinical grounds, and whether mutations in the Fused in […]
Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death
Sierra, Saleta,
Ramos, Maria C.,
Molina, Pilar,
Esteo, Cynthia,
Vázquez, Jose Antonio,
Burgos, Javier S.
There is growing evidence to support the hypothesis that statins may act as neuroprotectants in several neuropathological conditions, including Alzheimer’s disease. The mechanisms for neuroprotection are only partially understood, however, and pleiotropic phenomena could be involved. We have made a comparative study of 9 statins (lovastatin, mevastatin, pravastatin, simvastatin, cerivastatin, atorvastatin, fluvastatin, pitavastatin, and rosuvastatin), […]
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET
Shokouhi, S.,
Claassen, D.,
Kang, H.,
Ding, Z.,
Rogers, B.,
Mishra, A.,
Riddle, W. R.
Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
The effect of midlife physical activity on structural brain changes in the elderly
Rovio, Suvi,
Spulber, Gabriela,
Nieminen, Lasse J.,
Niskanen, Eini,
Winblad, Bengt,
Tuomilehto, Jaakko,
Nissinen, Aulikki,
Soininen, Hilkka,
Kivipelto, Miia
Physical activity has been associated with decreased dementia risk in recent studies, but the effects for structural brain changes (i.e. white matter lesions (WML) and/or brain atrophy) have remained unclear. The CAIDE participants were a random population-based sample studied in midlife and re-examined on average 21 years later (n=2000). A subpopulation (n=75; 31 control, 23 […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors
Reijmer, Yael D.,
van den Berg, Esther,
de Bresser, Jeroen,
Kessels, Roy P. C.,
Kappelle, L. Jaap,
Algra, Ale,
Biessels, Geert Jan
Background: Type 2 diabetes mellitus is associated with an increased risk of cognitive decline and dementia. We examined brain imaging correlates and vascular and metabolic risk factors of accelerated cognitive decline in patients with type 2 diabetes.; Methods: Cognitive functioning and brain volume as well as metabolic and vascular risk factors were assessed twice in […]
Platelet decline as a predictor of brain injury in HIV infection
Ragin, Ann B.,
D’Souza, Gypsyamber,
Reynolds, Sandra,
Miller, Eric,
Sacktor, Ned,
Selnes, Ola A.,
Martin, Eileen,
Visscher, Barbara R.,
Becker, James T.
An association between platelet decline and increased risk of progression to dementia has been observed in an advanced HIV infection cohort study. This investigation evaluated the prognostic significance of platelet decline for dementia, for psychomotor slowing, and for brain injury, as quantified in vivo, in a much larger population of HIV+ men. Platelet counts and […]
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, Rik,
Prins, Niels D.,
Pijnenburg, Yolande A.L.,
Lemstra, Afina W.,
van der Flier, Wiesje M.,
Adriaanse, Sofie F.,
Windhorst, Albert D.,
Handels, Ron L.H.,
Wolfs, Claire A.G.,
Aalten, Pauline,
Verhey, Frans R.J.,
Verbeek, Marcel M.,
van Buchem, Mark A.,
Hoekstra, Otto S.,
Lammertsma, Adriaan A.,
Scheltens, Philip,
van Berckel, Bart N.M.
Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]